Is 2185.HK overvalued or undervalued?

2185.HK currently has a P/E ratio of -3.58. Relative to the sector average of 26.80, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Shanghai Bio-heart Biological Technology Co., Ltd. stock?

Shanghai Bio-heart Biological Technology Co., Ltd. trades on HKSE. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 2185.HK?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 2185.HK protect my money against local inflation?

Many investors in Latin America buy international stocks like 2185.HK to protect their purchasing power. Because 2185.HK is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 2185.HK shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 2185.HK a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 2185.HK diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks2185.HK

Shanghai Bio-heart Biological Technology Co., Ltd.

HK$1.31+HK$0.02+1.56%

HKSE / HKD

Market cap

HK$308M

P/E

-3.6

EPS (TTM)

HK$-0.04

Dividend yield

0.00%

Beta

0.09

1Y return

-83.83%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$02021

$02022

$02023

$02024

$6M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.45Low
Current ratio23.75
Cash ratio6.02
Net margin-196.4%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

2185.HK-3.6
Healthcare sector median26.8
S&P 50022.0

Trades about 113% below its sector, cheaper than its peers on earnings.

Ratios

PEG-0.27
Price to book0.67
EPS (TTM)HK$-0.04
Payout ratio0%
FCF yield-5.76%

Range & risk

HK$1.28HK$9.10

Trading in the lower third of its 52-week band

Beta0.09

Profile

What Shanghai Bio-heart Biological Technology Co., Ltd. actually does

Based in the People's Republic of China, Shanghai Bio-heart Biological Technology Co., Ltd. is a medical technology firm specializing in interventional cardiovascular devices. Its core business revolves around delivering bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies to address conditions like coronary artery diseases and persistent, uncontrolled high blood pressure. The company's product pipeline features Bioheart, a BRS system designed for percutaneous coronary interventions for coronary artery disease; Iberis 2nd, a multi-electrode RDN product candidate; and a sirolimus drug-eluting balloon catheter intended for managing in-stent restenosis. Furthermore, the company has partnered with Terumo (China) Investment Co., Ltd. to conduct clinical trials for Iberis 2nd. Shanghai Bio-heart Biological Technology Co., Ltd. was established in 2014 and maintains its headquarters in Shanghai, China.

CEO

Li Wang

Employees

Headquarters

Shanghai, SH

Founded

2021-12-23

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 2185.HK and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

2185.HK has a beta of 0.09, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

Shanghai Bio-heart Biological Technology Co., Ltd.